Forbion Capital Partners has announced the final close of a new fund which will invest in late-stage European assets developing therapies for high medical need. The Forbion Growth Opportunities Fund I closed at €360 million, having only been launched in July 2020. Investors included Pantheon Ventures, the European Investment Fund, and Eli Lilly and Co, amongst others.
